Apraglutide for SR-aGvHD: Results from the phase II STARGAZE trial

During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiberg, Freiberg, DE, about results from the phase II STARGAZE trial investigating apraglutide, a GLP-2 analog in steroid-refractory lower-gastrointestinal acute graft-versus-host disease.

Zeiser discussed the background and rationale of the trial, including endpoint selection. He then discusses the safety and efficacy results, including the stability of response to Days 56 and 91 of the trial, and future clinical trials.